Uncategorized

Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers

Published

on

Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs targeting autoimmune diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version